Investor Center Home

Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Change Stock is Down 0.08
(%)Volume (0.66%)620,080
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
02/22/17Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic CancersPrinter Friendly Version
02/21/17Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product CandidatePrinter Friendly Version
01/31/17Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of GrowthPrinter Friendly Version
12/19/16Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell TherapiesPrinter Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
2017 BMT Tandem Meetings


12/05/16 12:15 p.m. PT
Bellicum ASH Investor & Analyst Lunch
Click here for webcast
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources